Hanna Koivunoro

United Therapeutics (United States)

Papers

1

Total Citations

18

H-Index

1

About

Dr. Hanna Koivunoro is a leading figure in the advancement of boron neutron capture therapy (BNCT), a targeted form of radiation oncology. Her primary research focuses on the clinical translation and dosimetry of BNCT, particularly for treating aggressive cancers like glioblastoma and head and neck tumors. Dr. Koivunoro’s most significant contribution is her comprehensive review of the Finnish BNCT experience, which analyzed outcomes for 249 patients treated at Helsinki University Hospital using reactor-based neutrons and the boron carrier l-BPA-F. This seminal work, cited 18 times, provides crucial long-term clinical data that bridges the gap between historical reactor-based BNCT and modern accelerator-based systems. Her research has been instrumental in demonstrating the therapy’s safety and efficacy, directly supporting the global transition to more accessible proton accelerator-based BNCT facilities. Dr. Koivunoro’s work is foundational for researchers and clinicians seeking to optimize BNCT protocols and expand its clinical application, marking her as a key contributor to the renaissance of this innovative cancer treatment modality.

Research Focus

Key Achievements

1
H-Index
1
Papers
18
Total Citations
18
Avg Citations/Paper
🏆 Most Cited Paper
From Nuclear Reactor-Based to Proton Accelerator-Based Therapy: The Finnish Boron Neutron Capture Therapy Experience
18 citations · 2022
📈 Most Prolific Year: 2022 (1 Papers)
🤝 Key Collaborators: 9
🏛 Institutions: United Therapeutics (United States)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 14 days ago